AkbogaMKDemirtasKYaylaCUnalS. Is endocan an inflammatory marker or an angiogenic marker, or both or none?Angiology. 2018;69(1):87.
2.
GokMKundiHKiziltuncETopcuogluCOrnekE. Endocan levels and coronary collateral circulation in stable angina pectoris: a pilot study. Angiology. 2018;69(1):43–48.
3.
KundiHGokMKiziltuncE, et al.The relationship between serum endocan levels with the presence of slow coronary flow: a cross-sectional study. Clin Appl Thromb/Hemostas. 2017;23(5):472–477.
4.
KundiHBalunACicekciogluH, et al.Admission endocan level may be a useful predictor for in-hospital mortality and coronary severity index in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68(1):46–51.
5.
NacarABEraymanAKurtM, et al.The relationship between coronary collateral circulation and neutrophil/lymphocyte ratio in patients with coronary chronic total occlusion. Med Principles Pract. 2015;24(1):65–69.
6.
KalkanMEŞahinMKalkanAK, et al.The relationship between the neutrophil–lymphocyte ratio and the coronary collateral circulation in patients with chronic total occlusion. Perfusion. 2014;29(4):360–366.
7.
KundiHGokMKiziltuncECetinMOrnekE. Association of IGF-1 with coronary collateral circulation in stable coronary artery disease. Biomarkers Med. 2017;11(7):527–534.
8.
GulecSOzdemirAOMaradit-KremersH, et al.Elevated levels of C-reactive protein are associated with impaired coronary collateral development. Eur J Clin Invest. 2006;36(6):369–375.
9.
KernerAGrubergLGoldbergA, et al.Relation of C-reactive protein to coronary collaterals in patients with stable angina pectoris and coronary artery disease. Am J Cardiol. 2007;99(4):509–512.
